drugset / Trial / NCT01045902

BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia

NCT01045902

Phase 3 Completed 139 enrolled Bayer
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this trial is to determine the efficacy and safety of Moxifloxacin in comparison to Sulbactam/Ampicillin in the treatment of pulmonary abscesses and aspiration pneumonia.

Timeline

Start
2001-02
Primary completion
Completion
2005-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ampicillin Unknown Intravenous
Subject Moxifloxacin Small molecule 400 mg Intravenous
Comparator Sulbactam Small molecule Intravenous